ReViral

Pfizer to acquire antiviral biopharma with HQ in Durham for up to $525M

Posted by WRAL TechWire | Apr 7, 2022

Drug giant Pfizer Inc. (NYSE: PFE) is acquiring Durham-based antiviral biopharma ReViral in a deal worth as much as $525 million, the companies announced early Thursday.

Biotech firm ReViral, with HQ in Durham, raises $44M in Series C funding

Posted by WRAL News | Aug 27, 2020

The round was led by CR-CP Life Science Fund. Additional investors included Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors.

ReViral

Pfizer to acquire antiviral biopharma with HQ in Durham for up to $525M

Biotech firm ReViral, with HQ in Durham, raises $44M in Series C funding

Categories

Tags